Dr Alan Lyss details the results and clinical implications of the EMERALD, PHOEBE, and DESTINY-Breast03 trials.
Patients with germline BRCA2 mutations had relatively worse outcomes with endocrine therapy and CDK4/6 inhibitors in the first-line setting and all lines of therapy.
An analysis of patients in the INSEMA trial sought to determine the impact of no SLNB vs SLNB and SLNB alone vs SLNB with ALND on quality of life for patients with breast cancer.
A prospective study sought to determine the significance of race on the risk of developing lymphedema and disease severity in women with breast cancer.
A single-arm cohort study sought to determine the efficacy of adding samuraciclib to treatment for ER-positive and/or PGR-positive, HER2-negative breast cancer.
Liquid biopsies were used to determine whether ctDNA analysis was predictive of disease progression in women with HR+/HER2- breast cancer.
Monitoring circulating mutated ESR1 enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Researchers presented updated findings from the DESTINY-Breast03 trial.
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
An analysis of a cohort of patients from the MONALEESA-2 trial sought to determine the efficacy of adding ribociclib to letrozole for HR+/HER2- breast cancer.
The delay in clip placement was associated with significant anxiety among the patients who were interviewed.
This meta-analysis was conducted on data from 4 clinical trials including more than 7000 women with ER+ breast cancer.
The researchers found that targeted therapies matched to genomic alterations in ESCAT tier I/II significantly improved progression-free survival.
Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.
Researchers evaluated outcomes for patients with breast cancer who were treated with a modern approach compared with a historical standard approach.
A subgroup analysis of the KEYNOTE-355 trial sought to determine which patients with metastatic TNBC would benefit from treatment with pembrolizumab and chemotherapy.